Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?

The article compares brokerage analyst recommendations (ABR) with Zacks Rank, arguing that while Gilead Sciences has a strong Buy-equivalent ABR of 1.52 from 31 firms, brokerage recommendations suffer from positive bias due to institutional conflicts of interest. The Zacks Rank, based on earnings estimate revisions rather than analyst opinions, is presented as a more reliable predictor of near-term stock performance. Gilead received a Zacks Rank #1 (Strong Buy) rating due to a 40.4% increase in consensus earnings estimates over the past month.